RT Journal
A1 Yates TA, Sonnabend J
T1 TReatment of human immunodeficiency virus in adults
JF JAMA
JO JAMA
YR 2012
FD October 17
VO 308
IS 15
SP 1522
OP 1523
DO 10.1001/jama.2012.12886
UL http://dx.doi.org/10.1001/jama.2012.12886
AB 
To the Editor: While the Strategic Timing of Antiretroviral Treatment (START)1 and other trials are being conducted, decisions on the initiation of antiretroviral treatment at higher CD4 cell counts must rest on complex observational evidence. Without randomization, individuals who initiate treatment early may be systematically different from those who initiate treatment later. We are concerned that publication of the recent update to the International Antiviral (formerly AIDS) Society–USA (IAS-USA) Panel's recommendations2 may slow recruitment to ongoing randomized controlled trials by suggesting there is no longer equipoise.